NGEN:CC News and Press, Nervgen Pharma Corp.

Completed End-of-Phase 2 meeting with the FDA; Company expects to provide a regulatory update in early 2Q 2026 and remains on track to initiate a Phase 3 study in chronic tetraplegia in mid-2026. Company expects to present clinical data from independent, blinded biomechanical gait analyses ...

2026-03-17 12:19:37 ET Thesis NervGen Pharma Corp. ( NGEN ) is a biotech company that is still in the clinical stage and is working on treatments to repair nerve damage. When I last wrote about the stock, I called it a Strong Buy because its main drug, NVG-291 , ...

Fennec Pharmaceuticals Inc. (FRX:CA) is expected to report $0.04 for Q4 2025 NervGen Pharma Corp. (NGEN:CA) is expected to report $-0.09 for Q4 2025 High Tide Inc. (HITI:CA) is expected to report $0.01 for Q1 2026 Encore Energy Corp. (EU:CA) is expected to report $-0.09 for Q4 2025 ...

The Company’s common shares will continue to trade on Nasdaq under the symbol “NGEN” No action is required; all shareholders, including Canadian shareholders, will continue to maintain full trading access on Nasdaq VANCOUVER, British Columbia, March 12, 2026 (GLOBE NEW...

Akita Drilling Ltd. Class A Non-Voting Shares (AKT.A:CA) is expected to report $0.02 for Q4 2025 Constellation Software Inc. (CSU:CA) is expected to report $40.88 for Q4 2025 Rubellite Energy Corp. (RBY:CA) is expected to report $0 for Q4 2025 Fennec Pharmaceuticals Inc. (FRX:CA) is e...

VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and ot...

Propel Holdings Inc. (PRL:CA) is expected to report $0.57 for Q4 2025 K92 Mining Inc. (KNT:CA) is expected to report $0.44 for Q4 2025 Foraco International SA (FAR:CA) is expected to report $0.05 for Q4 2025 NexGen Energy Ltd. (NXE:CA) is expected to report $-0.04 for Q4 2025 Nerv...

Whitecap Resources Inc. (WCP:CA) is expected to report $0.19 for Q4 2025 Gran Tierra Energy Inc. (GTE:CA) is expected to report $-0.22 for Q4 2025 NervGen Pharma Corp. (NGEN:CA) is expected to report $-0.05 for Q4 2025 Emera Incorporated (EMA:CA) is expected to report $0.58 for Q4 202...

NervGen Pharma Corp. (NGEN:CA) is expected to report $-0.05 for Q4 2025

VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and oth...